Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 40 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $312.00 thousand which beat the analyst consensus estimate of $270.00 thousand by 15.56 percent. This is a 131.11 percent increase over sales of $135.00 thousand the same period last year.
Evogene Q2 EPS $(0.21) Misses $(0.17) Estimate, Sales $312.00K Beat $270.00K Estimate
Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 40 percent decrease over losses of $(0.15) per share from the same
